Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/57452
Title: Short Communication: Impact of Viral Load Use on Treatment Switch in Perinatally HIV-Infected Children in Asia
Authors: Thahira Jamal Mohamed
Sirinya Teeraananchai
Stephen Kerr
Wanatpreeya Phongsamart
Nik Khairulddin Nik Yusoff
Rawiwan Hansudewechakul
Penh Sun Ly
Lam Van Nguyen
Tavitiya Sudjaritruk
Pagakrong Lumbiganon
Viet Chau Do
Nia Kurniati
Nagalingeswaran Kumarasamy
Dewi Kumara Wati
Moy Siew Fong
Revathy Nallusamy
Azar Kariminia
Annette H. Sohn
Keywords: Immunology and Microbiology
Medicine
Issue Date: 1-Mar-2017
Abstract: © 2017, Mary Ann Liebert, Inc. 2017. We sought to assess the impact of routine HIV viral load (VL) monitoring on the incidence of switching from a first- to a second-line antiretroviral therapy (ART) regimen, and to describe factors associated with switch. Data from a regional cohort of 16 clinical programs in six Asian countries were analyzed. Second-line switch was defined as a change from a non-nucleoside reverse transcriptase inhibitor (NNRTI) to a protease inhibitor (PI) or vice versa, and ≥1 of the following: (1) reported treatment failure by local criteria, (2) switch of ≥1 additional drug, or (3) a preceding HIV VL ≥1,000 copies/ml. Routine VL was having ≥1 test after ≥24 weeks of ART and ≥1 time/year thereafter. Factors associated with time to switch were evaluated with death and loss to follow-up as competing risks. A total of 2,398 children were included in this analysis. At ART initiation, the median (interquartile range) age was 6.0 (3.3-8.9) years, more than half had WHO stage 3 or 4, the median CD4 was 189 (47-456) cells/mm3, 93% were on NNRTI-based first-line ART, and 34% had routine VL monitoring. Treatment switch occurred in 17.6% of patients, at a median of 35 (22-49) months. After adjusting for country, sex, first ART regimen, and CD4% at ART initiation, children with routine VL monitoring were 1.46 (95% confidence interval 1.11-1.93) times more likely to be switched (p = .007). Scale-up of VL testing will lead to earlier identification of treatment failure, and it can help guide earlier switches to prevent resistance.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85014491256&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/57452
ISSN: 19318405
08892229
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.